Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katia A Mesquita

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery|January 31, 2013
Mitochondria in cancer stem cells: a target for therapyRute Loureiro, Katia A Mesquita, Paulo J Oliveira, et al.
Seminars in Cancer Biology|July 5, 2017
Mitochondrial biology in cancer stem cellsRute Loureiro, Katia A Mesquita, Silvia Magalhães-Novais, et al.
Plos One|May 24, 2011
In vitro surfactant structure-toxicity relationships: implications for surfactant use in sexually transmitted infection prophylaxis and contraceptionÂngela S Inácio, Katia A Mesquita, Marta Baptista, et al.
Cancer Letters|November 1, 2019
PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancersReem Ali, Muslim Alabdullah, Adel Alblihy, et al.
Biomedical Materials (Bristol, England)|August 21, 2023
Human adipose-derived mesenchymal stem cells laden in gellan gum spongy-like hydrogels for volumetric muscle loss treatmentOmar Alheib, Lucilia P da Silva, Katia A Mesquita, et al.
Acta Biomaterialia|March 12, 2022
Injectable laminin-biofunctionalized gellan gum hydrogels loaded with myoblasts for skeletal muscle regenerationOmar Alheib, Lucília P da Silva, Alain da Silva Morais, et al.
Oncotarget|May 31, 2015
Melatonin antiproliferative effects require active mitochondrial function in embryonal carcinoma cellsRute Loureiro, Silvia Magalhães-Novais, Katia A Mesquita, et al.
Cancer Research|October 10, 2018
Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma <i>In Situ</i> Induces Synthetic Lethality and ChemopreventionReem Ali, Abdulbaqi Al-Kawaz, Michael S Toss, et al.
Gynecologic Oncology|February 25, 2019
ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancersKatia A Mesquita, Muslim Alabdullah, Michaela Griffin, et al.
Cancers|August 14, 2019
ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast CancersTarek M A Abdel-Fatah, Reem Ali, Maaz Sadiq, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery|January 31, 2013
Mitochondria in cancer stem cells: a target for therapyRute Loureiro, Katia A Mesquita, Paulo J Oliveira, et al.
Seminars in Cancer Biology|July 5, 2017
Mitochondrial biology in cancer stem cellsRute Loureiro, Katia A Mesquita, Silvia Magalhães-Novais, et al.
Plos One|May 24, 2011
In vitro surfactant structure-toxicity relationships: implications for surfactant use in sexually transmitted infection prophylaxis and contraceptionÂngela S Inácio, Katia A Mesquita, Marta Baptista, et al.
Cancer Letters|November 1, 2019
PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancersReem Ali, Muslim Alabdullah, Adel Alblihy, et al.
Biomedical Materials (Bristol, England)|August 21, 2023
Human adipose-derived mesenchymal stem cells laden in gellan gum spongy-like hydrogels for volumetric muscle loss treatmentOmar Alheib, Lucilia P da Silva, Katia A Mesquita, et al.
Acta Biomaterialia|March 12, 2022
Injectable laminin-biofunctionalized gellan gum hydrogels loaded with myoblasts for skeletal muscle regenerationOmar Alheib, Lucília P da Silva, Alain da Silva Morais, et al.
Oncotarget|May 31, 2015
Melatonin antiproliferative effects require active mitochondrial function in embryonal carcinoma cellsRute Loureiro, Silvia Magalhães-Novais, Katia A Mesquita, et al.
Cancer Research|October 10, 2018
Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma <i>In Situ</i> Induces Synthetic Lethality and ChemopreventionReem Ali, Abdulbaqi Al-Kawaz, Michael S Toss, et al.
Gynecologic Oncology|February 25, 2019
ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancersKatia A Mesquita, Muslim Alabdullah, Michaela Griffin, et al.
Cancers|August 14, 2019
ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast CancersTarek M A Abdel-Fatah, Reem Ali, Maaz Sadiq, et al.
Pageof 2